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Complexes* 
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(From the Department of  Pathology,  New York University  School of Medicine,  New York 10016 and 
The American National Red Cross Blood Research  Laboratory,  Bethesda,  Maryland 20014) 
Previous reports from this laboratory showed that antigen (Ag)-antibody (Ab)  1 
precipitates  could be solubilized by the complement cascade  (complement-me- 
diated release activity or CRA) (1, 2). Based on several lines of indirect evidence, 
we proposed that CRA was due to the incorporation  of C3 fragments onto the 
Ag-Ab lattice rather  than  to extensive proteolysis of the Ag or Ab (2,  3).  We 
show here that,  indeed, during the release reaction,  a properdin and factor B- 
dependent C3-convertase is assembled on the immune precipitates.  Its interac- 
tion with purified C3 results in the incorporation of large amounts of C3 into the 
Ag-Ab lattice. The final step of the reaction is a "spontaneous" solubilization of 
the  C3-containing  immune  precipitates,  which  takes place  in  the  absence  of 
serum or divalent cations. 
Materials  and Methods 
Diluents  and  Other Reagents.  CRA  assays were carried out in  phosphate buffered saline 
(PBS), pH 7.4,  containing 0.1% gelatin, 1.5  x  10 -4 M Ca  ++ and 5  x  10  .4 M Mg  ++ (GPB++).  PBS 
containing 0.01 M EDTA or 0.01 M EGTA plus 0.005 M MgC12, pH 7.4, and 0.1% gelatin were also 
used for CRA assay (EDTA-GPB or EGTA-GPB). Isotonic veronal buffer containing 5% glucose, 
0.1% gelatin, 1.5  x  10  -4 M Ca  ++ and 5 x  10  -4 M Mg  ++ (DGVB  +÷) was used for hemolytic assays. 
Sheep erythrocytes (E)  were obtained from the New York  City Department of Health. Rabbit 
antibody (A) to E was purchased from Cordis Laboratories, Miami, Fla. 
Immune Precipitates.  Monomeric bovine serum albumin (BSA) was purified by two successive 
gel  filtrations on  Sephadex G-100  columns from BSA  (2  x  crystallized,  Pentex Biochemical, 
Kankakee, Ill.). IgG was isolated from rabbit antisera to BSA by ammonium sulfate precipitation 
and DEAE-cellulose column chromatography. A small amount of contaminating gamma globulin 
aggregates was removed by Sephadex G-100 gel filtration. 
Quantitative precipitation reactions were performed to determine the antibody contents of the 
IgG fraction of  the antisera to BSA. Immune complexes were prepared by mixing equal volumes of 
labeled or unlabeled BSA with anti-BSA in  the presence of 0.01  M  EDTA.  The  mixture  was 
incubated at 37°C for 30 min, then at 4°C overnight. The amounts of antigen and antibody were 
* Supported by grants no. A1 08499 and CA 16247. 
Abbreviations  used in thispaper: A or Ab, antibody; Ag, antigen; BSA, bovine serum albumin; 
C, complement; C3b, C3 fragment; CRA, complement-mediated  release activity; DGVB  ++, isotonic 
veronal buffer containing glucose, gelatin, and Ca  +÷, Mg+÷; E, sheep erythrocytes; EAC, erythro- 
cyte antibody complement; GPB  +÷, PBS to which 0.1% gelatin was added; Hus, human serum; P, 
properdin; PBS, phosphate-buffered saline containing Ca  ÷+ and Mg+÷; SFU, site-forming units. 
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calculated to yield complexes at equivalence. The molecular ratio of antibody to antigen was about 
2.4. 
Complement Reagents.  Human serum was used as the source of complement. Pooled human 
serum was stored in small aliquots at  -70°C until use. Human C3 was purified as in (4). After 
labeling, it showed a single band by SDS-acrylamide gel electrophoresis. Its sp act was 9.5  ×  1012 
site-forming units (SFU)/mg. Other complement components, guinea pig C1, human C4, C2, C3, 
C5, C6, C7, C8, and C9 were purchased from Cordis Laboratories. C3b was prepared by treatment 
of C3 with trypsin for a short time as described in (5). Properdin (P) was purified from pooled hu- 
man serum by the method of Pensky et al. (6). ~2SI-labeled P gave a single symmetrical peak when 
analyzed in SDS-polyacrylamide gel electrophoresis. The apparent mol wt was 44,000  daltons 
which corresponds to the monomeric subunit of P  (7). Contaminating proteins, as judged by dis- 
tribution of radioactivity, were less than 1%. The protein concentration of P was adjusted to 0.36 
mg/ml. P was stored at 4°C after it had been filtered through a  Millipore membrane. 
Antisera.  Rabbit  antiserum to human  factor B  was purchased from Behring Diagnostics, 
Sommerville, N.  J.  Rabbit antiserum to human C2  was a  gift from Dr.  C.  Alper. It had been 
thoroughly absorbed with C2-deficient  human serum. Anti-P was raised in rabbits by injecting 0.2 
mg of purified P  emulsified in  Freund's complete adjuvant  into  their foot pads.  Anti-P was 
absorbed with IgG since it contained small amounts of antibodies to IgG, as determined by double 
diffusion in agar  against normal human  serum and purified IgG.  The IgG fractions from all 
antisera were purified by DEAE-cellulose column chromatography. 
CRA Assays.  CRA assays were carried out as already described (1,  2).  In kinetic studies, 
immune precipitates were added to diluted human serum preincubated for 10 min at the indicated 
temperature. Then, 0.05-0.2-ml aliquots were taken at selected times and immediately mixed with 
2-4  vol of cold diluent containing 0.025%  of sheep erythrocytes. Supernates and pellets were 
separated by centrifugation (2,000 g, 4°C) and assayed for radioactivity in a gamma counter. 
Preparation of  Intermediate Complexes of  the Release Reaction.  Immune precipitates bearing a 
C3-convertase were usually prepared by incubating immune precipitates containing about 50-100 
leg Ab with 8-16 ml of a  1:2 dilution of human serum at 37°C for 5-10 min. The incubation was 
terminated by adding 2 vol of cold diluent and then transferring the reaction tube to an ice-water 
bath kept at 0°C. The precipitates were centrifuged in the cold at 3,500 g  for 15 min, and washed 
three times with a  total volume of 32 ml of cold diluent. The resulting precipitates were resus- 
pended in cold GPB ++ and used immediately. 
Binding of 125I-C3 to Immune Precipitates  Incubated with Fresh Serum.  Two experimental 
protocols were used, in which the ratios of immune precipitate to serum varied widely. In the 
initial experiments 0.1 ml of immune precipitates containing 80/~g of Ab were added to 0.4 ml of a 
1:3 dilution of human serum prewarmed at 37°C, and containing 10  /~g of ~25I-labeled C3.  Under 
these conditions, the precipitates are not dissolved even after prolonged incubation at 37°C. 0.1-ml 
aliquots were taken from the tube at selected times and mixed with 0.2 ml of EDTA-GPB. Pellets 
were separated from supernates by centrifugation in the cold at 3,500 g  for 15 min. Pellets were 
washed twice with 0.4 ml EDTA-GPB and then counted for radioactivity. In other experiments, 
immune precipitates formed with 0.97/~g of J~I-BSA and 5.6/~g anti-BSA were incubated under 
the same conditions. The kinetics of  solubilization and ~25I-C3 uptake were investigated. 67% of  the 
added precipitates were solubilized after 90 min of  incubation. The amount of C3 specifically  bound 
at different times was then calculated, that is, C3 bound to immune precipitates incubated with 
serum minus C3 bound to immune precipitates incubated in EDTA-serum. 
Binding of 125I-Properdin.  Immune precipitates resuspended in 0.1 ml GPB  +÷ were incubated 
at 37°C with 2.0 ml of serum containing 1.2  pg of l~sI-P. 0.2-ml aliquots were taken at selected 
times and transfered to tubes containing 0.4 ml of cold GPB  +÷. The precipitates were isolated by 
centrifugation at  3,500 g  for 15  min and washed once with 0.4  ml cold GPB  ÷+.  The combined 
supernates and the washed precipitates were assayed for radioactivity. 
Hemolytic  Assay of C3.  EAC142 were prepared with guinea pig C1, human C4, and human 
C2 (8). To assay the hemolytic activity of C3, 0.2 ml of dilutions of the test samples were incubated 
with 0.2 ml of 0.9 × 10S/ml EAC142 at 30°C for 10 min. Then, 0.6 ml of a mixture of 200 U/ml of C5, 
C6,  C7, C8, and C9 were added and the incubation continued at 37°C for 60 min. The degree of 
hemolysis was determined spectrophotometrically at the wave length of 412 nm. 
Inactivation  of C3 by the Ag-Ab Bound C3-Convertase or by EAC142.  0.1 ml of a suspension of 
complexes bearing C3-convertase or 3 ×  10  s EAC142 in 0.1 ml was mixed with 0.4 ml of C3 (Cordis 88  SOLUBILIZATION  OF  IMMUNE  AGGREGATES  BY  COMPLEMENT 
Laboratories, 200 U/ml) at 30°C for 60 min. The supernate was isolated by centrifugation and the 
residual C3 titer was assayed as indicated above. 
Blocking of C3-Convertase Activity with Antisera to Factor B  and C2.  In preliminary experi- 
ments we compared the C3-convertase activity of EAC 142 and of  immune precipitates treated with 
excess serum for 6-10  min as described above.  We found that 3  ×  108  EAC142  and complexes 
containing 60 ~g of Ab had approximately the same activity in our assay, that is, they inactivated 
60-70%  of C3  added.  To  determine whether the  C3-convertase associated  with  the  immune 
complexes was C2-dependent or factor B-dependent, the following experiment was performed. 0.1- 
ml aliquots of immune-complex associated C3-convertase (60 t~g Ab) were incubated at 0°C for 60 
rain with 0.2 ml of  different dilutions of normal rabbit IgG or antibodies to C2 or factor B. Controls 
were set up incubating the complexes with diluent, in the absence of antibody. The precipitates 
were washed twice with cold buffer, and resuspended in 0.1 ml of DGVB  ÷÷ and assayed for C3- 
convertase activity. The specificity of the antisera was controlled by incubating 3  ×  l0  s EAC142 
cells with different dilutions of the IgG preparations under the same conditions. The erythrocytes 
were washed twice by centrifugation and assayed for C3-convertase as above. 
Iodination.  Monomeric BSA,  C3,  and P  were labeled with 125I or  ~31I by the chloramine-T 
method (9), as described in (10) except that the radiolabeling of C3 and P was carried out at 0°C. 
Radioactive BSA was stored at  -20°C and used within 4 wk. ~25I-C3 and ~25I-P were kept at 4°C. 
The sp act ranged between 105 and 10  e cpm/~g. 
Determination of C3 and Properdin in Serum.  The concentration of C3 in the pooled serum 
used in the present experiments was 0.84 mg/ml as determined by single radial immunodiffusion 
by  using  a  reference serum  (Behring Diagnostics).  The  concentration of P  was  24  ~g/ml  as 
measured by the radioimmunoassay described in (11). Purified P was used as the protein standard 
in this assay. 
Results 
Kinetics of Solubilization.  Fig.  1 illustrates the kinetics of solubilization of 
the immune precipitates (125I-BSA-anti-BSA)  in human  serum at 25  ° or 37°C. 
Solubilization did not occur at 25°C. At 37°C,  a  time lag of about 10 min was 
observed before the onset of the solubilization process. By the end of 15 min only 
12% of the immune precipitates had been solubilized while more than 50% were 
dissolved at 30 min.  The duration of the lag period varied in different experi- 
ments depending on the amount of immune precipitate used, the affinity of the 
antibody for the antigen, and the dilution and source of complement. Addition of 
0.01  M EGTA and Mg  +÷ to the reaction mixture markedly lengthened the lag 
period. 
Generation of a C3-Convertase Activity on the Immune Precipitates Precedes 
Solubilization.  The experiments shown in Fig. 2 demonstrate the presence of a 
C3-convertase on immune complexes obtained after 10 rain of incubation with 
serum,  at  a  time when  no solubilization had  occurred. The washed immune 
precipitates inactivated purified C3 in a  dose-dependent fashion. Controls con- 
taining the same amounts of immune precipitate but preincubated with EDTA- 
serum, inactivated less than 5% of the purified C3. 
The C3-Convertase Generated on the Immune Complexes is Factor B- and P- 
Dependent.  This was demonstrated in the experiments described in the legend 
of Fig. 3 and in Table I. Fig. 3 shows that the C3-convertase activity associated 
with the immune complexes is  almost completely inhibited by preincubation 
with antibody to factor B. A comparable amount of anti-C2 or normal rabbit IgG 
did not inhibit the C3-convertase by more than 5%. In contrast, the antiserum to 
C2,  but not to factor B, inhibited 90% of the C3-convertase activity associated 
with the EAC142 cells. M.  TAKAHASHI,  B.  F.  TACK,  AND  V.  NUSSENZWEIG 
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Fro.  1.  Kinetics of solubilization. The immune precipitates were prepared at equivalence 
with ~SI-labeled BSA and the IgG fraction of a rabbit antiserum to BSA. Washed immune 
precipitates containing 15 ~tg of Ab were added to 2 ml of a 1:2 dilution of human serum and 
incubated at 4°C,  25°C,  or 37°C.  0.2-ml aliquots were taken from the mixture at selected 
times, diluted with cold buffer, and centrifuged. Supernates and pellets were assayed for 
radioactivity.  In  serum  containing 0.01M  EGTA-5mM  Mg  ÷+,  solubilization occurs  at  a 
slower rate. No solubilization was observed when the mixture was incubated at 25°C or 4°C 
(not shown in this graph). In control tubes, which contained either heated serum (56°C, 30 
min) or 0.01M  EDTA-serum, 3.2 and 2.7% of the added immune precipitates, respectively, 
were solubilized after incubation at 37°C for 60 min. 
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FIG.  2.  Demonstration of C3 convertase activity associated with serum-treated immune 
precipitates. Immune precipitates (Imm. ppt.) containing about 100  @g of Ab were incu- 
bated at 37°C for 8-10 min with 16 ml of a  1:2 dilution of human serum. At this time, no 
solubilization was detected. The serum-treated precipitates were washed three times with 
cold GPB  ++  and resuspended in 0.2  ml of the same buffer. 0.1  ml of the suspension was 
incubated at 30°C for 60 rain with 0.4 ml of 200 U/ml of C3.  Supernates were separated by 
centrifugation,  and  the  residual  C3  was titrated by  hemolytic assay.  Control immune 
precipitates were preincubated with EDTA-serum under identical conditions, and then 
assayed for C3-convertase activity. Results of  three separate experiments are represented  in 
this figure. 90  SOLUBILIZATION  OF  IMMUNE  AGGREGATES  BY  COMPLEMENT 
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Fro.  3.  Blocking of C3-convertase activity associated  with  the  serum-treated  immune 
complexes or with EAC142 by antibodies to factor B or C2.  Several portions of immune 
precipitate were incubated at 37°C for 6 min with a h2 dilution of serum (6.0 ml of serum, 60 
~tg of complexed antibody), washed twice with cold buffer, and resuspended in 0.1 ml of cold 
GPB ++. These serum-treated immune complexes (60 ~g of Ab) or 3 × 108 EAC142 in 0.1 ml of 
GPB ÷+ were incubated at 0°C for 60 min with 0.2 ml of dilutions of either anti-factor B, anti- 
C2, normal rabbit IgG. The precipitates or cells were then washed twice with cold DGVB +÷ 
and resuspended in 0.1 ml of the same buffer and incubated at 30°C for 60 min with 0.4 ml 
of C3 (200 U/ml). The residual C3 activity in the supernate was assayed by hemolytic titra- 
tion. 
The  C3-convertase  activity associated  with  immune  precipitates  was  lost 
almost completely upon incubation at 37°C for 60 min (Table I). Partial recovery 
of activity was obtained by the addition of purified factor B. Addition of both P 
and B, however, restored the C3-convertase activity to the original level. 
Incorporation  of Properdin  into the Immune Precipitates.  The previous ex- 
periments showed that  P  and factor  B  restore  the  C3-convertase  activity of 
immune precipitates after decay at 37°C, and give further support for the finding 
that the C3-convertase associated with the complexes is alternative pathway- 
dependent. In Figs. 4 and 5 we show that P  is actually bound to the immune 
aggregates as part of the process which leads to solubilization, and that it is in 
part released upon reincubation at 37°C. 
Immune precipitates  were  incubated  at  37°C with  serum  to  which  trace 
amounts of ~25I-p had been added. Samples were taken at different times, mixed 
with cold diluent to stop the reaction, and centrifuged. The conditions chosen 
lead to solubilization of 80% or more of the precipitates after 60 min of incuba- 
tion. It is clear that P bound rapidly to the precipitates. The peak of  P incorpora- 
tion was reached in 8 min,  and at this time solubilization had only started. 
Solubilization reached completion only at 60 min. A considerable amount of P 
was added to the precipitates under these conditions. Assuming that ~25I-P and P 
in serum have the same affinity for the complexes, we calculated that at 8 min 
close to one molecule of P is bound per molecule of Ab in the complexes. 
Next we demonstrated directly the dissociation of P from immune aggregates 
upon incubation at 37°C. The conditions chosen for the binding of P are described 
in the legend of Fig. 5. After P had been incorporated, the immune aggregates M.  TAKAHASHI~  B.  F.  TACK~  AND  V.  NUSSENZWEIG 
TABLE  I 
Decay of Immune Complex-Associated  C3-Convertase Activity and 
Reconstitution with Factor B and Properdin 
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Initial treatment of  Second treatments  Addition of§  C3 Inactivation  H 
complexes* 
% 
Serum  GPB *÷, 0°C  -  90.0 
EDTA-Serum  GPB  +÷, 0°C  -  5.6 
Serum  EDTA, 37°C  -  11.7 
Serum  EDTA,  37°C  P  24.4 
Serum  EDTA, 37°C  B  32.3 
Serum  EDTA,  37°C  P, B  91.0 
* Immune complexes (700 ~g of Ab) were incubated for 6 rain at 37°C with 35 
ml  of a  1:2  dilution  of human  serum,  and  washed  in  GPB ÷+.  Then  the 
precipitates were resuspended in GPB ++, divided in portions, and treated as 
shown. 
100 ~g of washed immune complexes were incubated for 60 rain at indicated 
temperatures either in EDTA-GPB or GPB +÷.  After incubation they were 
washed with DGVB  ÷+. 
§ 10 ~g of B, 7.2 ~g of P. 
II Treated complexes were incubated at 25°C for 60 rain with 0.4 ml of C3 (200 
CH50/ml). The residual C3 was assayed by hemolytic titration. 
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FIG.  4.  Incorporation of P into the antigen-antibody lattice. Immune precipitates formed 
between 1.2 ~g of 13~I-BSA and 6.8 ~g of Ab to BSA were incubated at 37°C with 2.0 ml of a 
1:2 dilution of human serum to which 1.2 ~g ~25I-P had been added.  0.2-ml aliquots were 
taken at indicated times, mixed with 0.4 ml of cold buffer, and centrifuged. The conditions 
chosen lead to 80% or more solubilization of the precipitates. Q, percent properdin uptake; 
•  , percent solubilization. Control tubes contain EDTA-serum instead of serum; O, percent 
properdin uptake;  [3, percent solubilization. 
were washed at 0°C,  resuspended in GPB  ÷÷, and reincubated at different tem- 
peratures.  After  5  min  more  than  60%  of P  had  been  dissociated  into  the 
supernate. The dissociation of P  was much less pronounced at lower tempera- 
tures.  Similar results  were obtained when  lzsI-P-containing immune precipi- 
tates were incubated in the buffer containing 0.01  M EDTA (not shown). 
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FIG.  5.  Dissociation of P  from serum-treated immune complexes. Immune precipitates 
containing 600  ~g of complexed antibody were incubated at 37°C for 4 min with 0.4 ml of a 
1:4 dilution of human serum plus 1.2  ~g 1~I-P.  The precipitates were then separated by 
centrifugation, washed twice with cold GPB ÷+,  and resuspended in+0:~5 ml of the same 
buffer.  0.025-ml aliquots of this suspension were  added to  0.4  ml ,~f GPB ++  at different 
temperatures. At  different times 0.05-ml aliquots were  taken from the different tubes, 
diluted with 0.3 ml of cold buffer, centrifuged, and counted• Similar results were obtained 
when serum-treated immune precipitates were incubated in EDTA-GPB. 
Solubilization.  Washed  immune-precipitates bearing  C3-c6nvertase  activity 
were prepared as  described before, by incubating  the  precipitates in  human 
serum for 10 min at 37°C.  As shown in Fig. 6, when these washed precipitates 
were reincubated at 37°C with pure C3,  solubilization occurred. The reaction 
required no divalent cations, and proceeded in the presence of EDTA.  Control 
precipitates, preincubated in human serum for 4 min or with EDTA-serum for 10 
min,  and bearing no C3-convertase activity, were not solubilized when incu- 
bated  with  C3.  C3  purified to homogeneity (4)  was  used in  all these experi- 
ments. 
We also attempted to enhance the solubilization of immune complexes by the 
addition of cobra venom factor, or zymosan, or inulin, to the serum containing 
the immune precipitates. Addition of these substances, known as activators of 
the alternative pathway, strongly inhibited CRA of serum. Also, addition to the 
precipitates of purified C3b (obtained by trypsin treatment of C3), did not cause 
solubilization. Therefore, it appears that solubilization depends on the interac- 
tion of an immune complex-bound  C3-convertase and C3. 
Incorporation  of C3 into  the Immune Precipitates during the Solubilization 
Process.  Next we studied the kinetics of C3  incorporation into the immune 
aggregates incubated with serum•  As described in the Methods section, these 
experiments were performed either under conditions in which complement was 
limiting or in the presence of large excess of complement. 
0.1 ml of immune precipitates containing 80 ~g of Ab were incubated at 37°C 
with 0.4 ml of a  1:3 dilution of serum containing 10 ~g of 125I-labeled C3. Under 
these conditions (complement is limiting) less than 5% of the precipitates are 
solubilized after 90-min incubation at 37°C.  At 10 min, about 1.5% of the label M.  TAKAHASHI,  B.  F.  TACK,  AND  V.  NUSSENZWEIG  93 
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FIG. 6.  Solubilization of the serum-treated immune precipitates by C3.  Immune precipi- 
tates containing 11.2  /~g of complexed Ab were incubated with 2.0 ml of a  1:2 dilution of 
human serum at 37°C for 10 min. The serum-treated precipitates were then washed three 
times with 2 ml each of cold buffer and resuspended in 0.2 ml of GPB ÷+. 0,025-ml aliquots 
containing 0.2 ~g Ag and 1.1 ~g of Ab were then incubated for 50 min at 37°C with 0.2 ml of 
C3 at different concentrations, with GPB  +÷ (0, ~) or EDTA-GPB (©) as a diluent. Super- 
nates and pellets were then separated by centrifugation and assayed for radioactivity. 
Other controls consisted of immune precipitates preincubated with human serum contain- 
ing 0.01M  EDTA under the same conditions, washed, and then reacted with purified C3. 
The maximum solubilization induced by addition of C3 corresponds to 40% of the immune 
precipitates added. 
had been specifically incorporated into the aggregates (Fig. 7). Assuming that 
labeled and unlabeled C3 were equally active, the amount of C3 incorporated 
after 20-min incubation was 0.053 ~g/~g of  antibody. These values correspond to 
about one molecule of C3 per 18 antibody molecules, if we assume the mol wt for 
the C3 fragment bound to the complexes to be 180,000 daltons (C3b). 
Much larger amounts of C3 were incorporated into the immune precipitates 
under conditions which lead to solubilization, as shown in the following experi- 
ment. 0.1 ml of immune complexes (131I-BSA-anti-BSA,  containing 5.6  /zg Ab) 
were incubated at 37°C with 0.4 ml of  a 1:2 dilution of  human serum, and 20 ~g of 
125I-C3. The kinetics of 12~I-C3 uptake and solubilization of the precipitates is 
shown in Fig. 8. Under these conditions, 67% of the immune precipitates were 
solubilized in 90 min. At 30 min, 0.21 ~g of C3 had been specifically  bound to the 
aggregates containing 0.50  ~g of complexed Ab, and the molar ratio of Ab/C3 
was 2.5.  As will be shown in the next section, the amounts of C3 incorporated 
into  the  solubilized  complexes  is  even  higher,  that  is,  the  Ab/C3  ratio  is 
approximately one. 
The Final Step  of the Solubilization Process:  "Spontaneous" Release.  The 
preceding experiments demonstrate that different Ag-Ab-C intermediates are 
generated when Ag-Ab precipitates are incubated in serum at 37°C, and that 
after 6-10  min of incubation, the Ag-Ab bear  C3-convertase activity. Fig.  9 
shows  the  result  of an  experiment  in  which the  immune precipitates  were 
preincubated with serum for a  longer period of time (15 min). They were then 
washed three times with cold buffer and reincubated at different temperatures 94  SOLUBILIZATION  OF  IMMUNE  AGGREGATES  BY  COMPLEMENT 
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Fro.  7.  Kinetics of C3-binding to immune precipitates incubated with limited amounts of 
complement. Immune precipitates formed with 13.6 /zg of ~3~I-BSA and 80  ~g of Ab were 
incubated at 37°C with 0.4 ml of a 1:3 dilution of human serum plus 10 ~g of ~25I-labeled C3. 
Controls consisted of EDTA-serum containing the same amount of ~25I-C3. 0.1-ml aliquots 
were taken at  selected times, diluted,  and  centrifuged. Pellets were washed twice and 
counted for radioactivity. Under the conditions used tess than 5% of the immune precipi- 
tates were solubilized after 60 min of incubation. 
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FIG.  8.  C3-binding during solubilization. Immune precipitates formed with 0.97 ~g of ~3~I- 
BSA and 5.6 ~g of anti-BSA were incubated at 37°C with 0.4 ml of a  1:2 dilution of human 
serum plus 20  ~g of ~5I-C3.  Samples were taken at indicated times, diluted, and centri- 
fuged. Precipitates were washed three times with cold buffer. ~a~I-BSA and ~25I-C3 in the 
supernates and pellets were counted. The control tubes contained EDTA-serum plus x2~I-C3. 
Symbols used: percent of C3 total counts found in precipitate incubated in human serum (e) 
or EDTA-human serum (C)); percent of solubilization of precipitates incubated in human 
serum (m) or EDTA-human serum ([:]). 
for  various  lengths  of time.  In  contrast  with  the  solubilization of immune 
precipitates by serum (Fig. 1), this intermediate underwent solubilization with- 
out a  lag phase  upon reincubation at  37°C,  and  even at  25°C. This process, 
designated as spontaneous release, was almost completed within 20 min at 37°C. 
Spontaneous release requires no divalent cations. It is a  specific process, since M.  TAKAHASHI,  B.  F.  TACK,  AND  V.  NUSSENZWEIG  95 
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FIG.  9.  "Spontaneous" release of the immune precipitates which had been preincubated 
with human serum. The immune precipitates (15 ~g of Ab), prepared as explained in the 
legend for Fig.  1, were incubated at 37°C for 15 min with 2 ml of a  1:2 dilution of human 
serum.  The  serum-treated precipitates were  washed three  times  with  cold buffer  and 
resuspended in either GPB ÷+ or EGTA-GPB or EDTA-GPB. The mixture was then incu- 
bated at 2  °, 25  °,  or 37°C.  0.2-ml aliquots were taken at selected times, diluted with cold 
buffer, and centrifuged. Supernate and pellets were assayed for radioactivity. The maxi- 
mum  solubilization  attained  by  spontaneous release  corresponds to  about  50%  of the 
immune precipitates added. Controls, in which the same complexes had been preincubated 
at 25°C in serum or at 37°C in EDTA-serum showed no spontaneous release upon reincuba- 
tion at 37°C (880 and 1,090 cpm, respectively). 
immune precipitates which had been preincubated with fresh serum at 25°C, or 
at 37°C with serum containing 0.01 M EDTA were not solubilized upon reincuba- 
tion at 37°C in buffer. 
The Ab/C3 ratio among spontaneously solubilized complexes was determined 
in the following experiment. Immune precipitates prepared with 13.8/~g of 131I- 
BSA and 80.3/~g Ab were incubated with 16 ml of a 1:2 dilution of human serum 
containing ~25I-C3 (10  /~g). The conditions were chosen on the basis of prelimi- 
nary experiments which showed that more than 85% of these immune precipi- 
tates could be dissolved after 60 min of incubation with the serum at 37°C. After 
12 min, when solubilization had started, the reaction was stopped by addition of 
cold EDTA-GPB,  and pellets were washed three times with cold buffer. The 
washed precipitates were incubated with 2.0  ml of EDTA-GPB at 37°C for 40 
rain.  Supernates  were  assayed for  12sI and  131I and we  calculated that they 
contained 27.5/~g Ab and 33.5/~g of C3. Precipitation with specific antisera to Ig 
showed that 80% or more of the C3 molecules in these supernates were bound to 
Ig (1). The molar ratio of Ab to C3 is close to I assuming again that the mol wt of 
the fragments of C3 was 180,000 daltons. Very similar results were obtained in 
several other experiments. 
Discussion 
We show here that, as in the case of complement mediated cell lysis (12), the 
solubilization of immune aggregates by complement can be conveniently divided 
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Generation  of a  Solid-Phase  C3-Convertase.  As shown in Fig.  1,  immune 
precipitates are solubilized when incubated with serum at 37°C. This process 
starts after a  lag of a  few minutes and does not occur or is very inefficient at 
temperatures below 25°C. Solubilization is dependent on divalent cations. It is 
completely inhibited when both Ca  ++ and Mg  ++ are chelated with EDTA, and 
proceeds at a  slower rate in the absence at Ca  ++. During the lag period, a  C3- 
convertase is  generated on the complexes  (Fig.  2).  This was directly demon- 
strated by incubation of purified C3 with the washed precipitates obtained after 
10 min of interaction with serum at 37°C. This incubation lead to a considerable 
reduction of the hemolytic activity of C3 as compared to controls, in which C3 
had been exposed to immune aggregates treated with EDTA-serum for 10 min. 
A key finding was that the C3-convertase activity associated with the com- 
plexes was dependent on enzymes of the alternative pathway. C3 consumption 
by the complexes was completely inhibited if they had been previously incu- 
bated with an  antibody to factor B,  but  not by an antibody to  C2.  Controls 
showed  that  the  C3-convertase  assembled  on  the  erythrocyte  membranes 
(EAC142)  could be inhibited by anti-C2 but not by anti-B. 
Assembly of the enzyme on the complexes depended on divalent cations and 
occurred after incubation with serum for a few minutes. During this short time, 
factor  B  (Fig.  3),  P  (Fig.  4),  and  C3  (Fig.  8)  were  bound  to  the  immune 
aggregates. 
When the P, B, and C3-containing aggregates were separated from serum by 
centrifugation and  reincubated  at  37°C, the  C3-convertase  activity decayed 
(Table I). This decay did not occur at 0°C, and was much delayed at 15°C. With 
labeled P, we found that at 37°C P dissociated from the aggregates. After 5 min 
at 37°C, at a time when solubilization could not be detected, more than 60% of 
the labeled  P  was  found in the supernate  (Fig.  5).  However,  a  considerable 
proportion  of P  did  not  dissociate  from  the  immune  complexes  even  after 
prolonged incubation. The reasons for this observation are not known at pres- 
ent. Others have found that P has binding affinity for C3, C3b,  and C3c in the 
fluid phase (13) or on the cell membrane (14, 15). It has also been suggested that 
since P  is multivalent, at least two C3 molecules may be required to provide 
stable bonds between C3  and  P  (14, 16). Perhaps the fraction of P  which is 
strongly associated with the immune complexes formed multiple bonds with the 
acceptor molecules. 
The activity of  the decayed complexes could be fully restored by purified P and 
B but not by either of them alone. These findings support the idea that this C3- 
convertase, as found in other systems (16-19)  may be  a  multi-unit structure 
consisting of B, P, and probably C3b.  The finding that under conditions which 
lead to solubilization, the molecular ratios of P, C3, and Ig on the complexes was 
close to one, supports this concept. 
Since factor D is essential for solubilization (Takahashi, Brade, and Nussen- 
zweig, Manuscript in preparation), it is not clear why factor D was not required 
for the reconstitution of the C3-convertase activity after decay at 37°C (Table I). 
Perhaps, as in the case of the C3-convertase assembled on zymosan (20), some 
factor D may remain bound to the immune complexes after decay of factor B. 
Alternatively, our  preparations  of factor B  or  properdin  may contain trace 
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The observation that an alternative pathway-dependent (not C2-dependent) 
C3-convertase is assembled on the immune complexes explains our observations 
that the solubilization of immune precipitates is strictly Mg  ++, C3,  B  (1, 2), P 
and D dependent and that it cannot occur through the activity of the classical 
pathway alone (Takahashi, Brade, and Nussenzweig, Manuscript in prepara- 
tion). Since the activation of the classical pathway by cell-associated immune 
complexes leads to the formation of a membrane-associated C3-convertase (C42) 
(21, 22), it is not clear why this enzyme could not be detected on the immune 
aggregates.  2 The reasons for this may be trivial, that is, that the concentrations 
of factor B and C3 in serum are much higher than those of C2 and C4 respec- 
tively (12). Therefore, the number of C42 sites on the complexes may be smaller 
as  compared to the  C3bPB  sites.  Another possibility is that P  stabilizes the 
factor B-dependent convertase (15, 25), while the C2-associated enzyme decays 
more quickly since it is not provided with a comparable stabilizing mechanism. 
Amplification.  During this stage, which is not dependent on divalent cat- 
ions, the C3-convertase bound to the complexes interacts with C3 and additional 
fragments of C3 are bound to the complexes (Fig. 8).  After a  certain time lag 
solubilization occurs. We emphasize that the assembly of the C3-convertase on 
the complexes is necessary, but is not sufficient for solubilization. For example, 
in the experiments shown in Figs. 4 and 6, less than 5% of the immune precipi- 
tates taken at 4-10 rain were solubilized upon reincubation in the buffer after 
washing. However, these immune precipitates already contained a considerable 
amount of P, and had C3-convertase activity. 
It appears that the progressive accumulation of C3 fragments onto the lattice 
causes its disruption and the subsequent release into the fluid phase of soluble 
material containing Ag, Ab, and several C-derived peptides. The role of C3 as an 
effector molecule in solubilization is supported by several other observations: (a) 
solubilization does not occur in the absence of C3 and it does not require C5 (1, 
2); (b) CRA in the plasma of mice is closely correlated with its C3 concentration 
(3); and (c) a large proportion of the C3 moieties in the precipitate were found to 
be very tightly bound to the Ab.  C3-Ab  remained associated even after treat- 
ment with 8 M urea in 1% SDS for 1 h  at 60°C. The aggregates were resolved, 
however, by treatment with denaturing agents in the presence of dithiothreitol 
(Czop,  Tack, and Nussenzweig, Manuscript in preparation). 
Another important point is that solubilization of  immune precipitates does not 
occur if a  C3-convertase is generated simultaneously in the fluid phase by the 
addition of cobra-venom factor, inulin, or zymosan. Also purified C3b is ineffec- 
tive.  Therefore,  it  appears  that  only nascent  C3b,  generated by the lattice- 
associated convertase can effectively bind to and solubilize complexes. 
Spontaneous Release.  The final step of  the solubilization process is a second- 
ary reaction which takes place after a large amount of C3 fragments has already 
accumulated on the complexes. It occurs in medium devoid of serum proteins, 
and does not require free divalent cations. It proceeds at 25°C but is more rapid 
at  37°C (Fig.  9).  These  findings demonstrate that  the  fixation of C3  is  not 
2 However, as will be shown elsewhere (Takahashi, Brade, and Nussenzweig, Manuscript in 
preparation) the presence of C4 on the complexes could be directly demonstrated by the use of 
specific antisera.  Miiller-Eberhard and Lepow (23),  as well as Willoughby and Mayer (24) also 
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sufficient by itself for solubilization. Some further rearrangement of the lattice, 
whose nature is not clear, appears necessary. One simple explanation for the 
spontaneous release of complexes from the aggregate is that it is caused by the 
dissociation of a few primary Ag-Ab bonds. As shown before (2), primary Ag-Ab 
bonds markedly affect solubilization rates, which are much higher for precipi- 
tates prepared with antibodies of lower affinity for the antigen. It is conceivable 
that the tight binding of bulky C-peptides to the antibody molecules interferes 
with Ag-Ab bonds, either by steric interference  with the binding of antigen and/ 
or by inducing allosteric changes in the combining site.  In addition, these C 
components may interfere with the movement of the Fab arms around the hinge 
region and thereby prevent cross-linking of the Ag molecules. 
In summary, it appears that solubilization is mediated through the binding of 
C3b to the immune complex. After spontaneous dissociation of antigen from 
antibody, the presence of C3 peptides on the antibody may prevent reassociation 
and cross-linking with antigen. It is important to determine which domains of 
the antibody molecule are associated with C3 fragments. If  they are bound to the 
Fab  portion of the molecule, in proximity to the combining site,  they could 
directly interfere with binding of antigen. However, it should be pointed out 
that C3b fragments may also interfere with lattice formation by inhibiting Fc-Fc 
nonspecific interactions which occur during precipitation (26). It is also conceiv- 
able that the binding of a relatively large number of complement peptides on to 
the immune aggregates modifies their overall solubility and favors dissociation. 
Therefore, it  is  still  unresolved whether primary Ag-Ab bonds are  affected 
during the solubilization process. 
Finally, it should be emphasized that although the process of solubilization 
cannot be  mediated through the  classical pathway alone,  it  is  a  combined 
function of both the classical and properdin pathways. In the absence of Ca  ++, 
C4, or C2, selubilization is much less effective. As will be shown in a succeeding 
paper,  the role of the classical pathway may be to prime the complexes by 
depositing some C3b molecules on the antibody, which will then become nuclei 
for the assembly of the alternative pathway C3-convertase (Takahashi, Brade, 
and Nussenzweig, Manuscript in preparation). Therefore, deficiencies in either 
the classical or alternative pathway will affect the process of solubilization of 
immune aggregates. 
Summary 
During the solubilization of immune precipitates BSA-rabbit antibodies to 
BSA by human complement, at least three stages can be distinguished.  (A) 
Generation of alternative pathway  C3-convertase  sites  associated with  the 
immune complexes. During the first minutes of interaction between the im- 
mune aggregates and serum, before any solubilization has taken place, proper- 
din (P), factor B, and C3 moieties are incorporated into the lattice. The washed 
precipitates have C3-convertase activity, which can be completely inhibited by 
antibodies to factor B, but not to C2. The assembly of the convertase is tempera- 
ture-dependent, and does not take place in the absence of Mg  ++. The immune 
complex-associated C3-convertase activity decays rapidly at 37°C, but it can be 
restored by addition of purified factor B and properdin. (B) Amplification. When M.  TAKAHASHI,  B.  F.  TACK,  AND  V.  NUSSENZWEIG  99 
the aggregates bearing C3-convertase are incubated with purified C3, solubiliza- 
tion takes place. It appears that solubilization is caused by the accumulation of a 
large number of C3 fragments on the Ag-Ab lattice.  In solubilized complexes, 
the molar ratios of Ab/C3 are close to one.  (C) Spontaneous release. The final 
step  in the  solubilization  process is  a  secondary reaction,  during  which  some 
rearrangement of the lattice takes place. It occurs in medium devoid of serum 
and does not require divalent cations. 
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